我們已在上線！進一步了解

Kymera Therapeutics

KYMR

市值 US$87.1億

104.78 USD

-3.36

3.11%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

105.00

+0.22

0.21%

1天

-3.11%

5天

-6.12%

1個月

-9.93%

3個月

-8.08%

6個月

21.64%

今年迄今

44.01%

1年

73.3%

5年

94.29%

10年

215.03%

關於： Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

員工： 273

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 22.2%

中性 72.2%

負面 5.6%

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation seeks to determine whether Kymera Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Zacks Investment Research

Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?

Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?

Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

Can KT-621 Mark a Turning Point for Kymera Therapeutics?

KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.

Can KT-621 Mark a Turning Point for Kymera Therapeutics?

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 21st Annual Healthcare Conference in Boston, MA on September 9 at 8:00 AM ET; Citi 2026 Biopharma Back to School Summit in New York, NY on September 10 at 11:20 AM ET; H.C.

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected in late 2027 WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present two posters featuring previously reported data from the BroADen Phase 1b trial evaluating KT-621, its first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD).

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Zacks Investment Research

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript

查看新聞排名

價格圖表採用Lightweight Charts™實作